A Phase 3 interventional study of Placebo and LX211 in Uveitis, Posterior, Uveitis, Intermediate and Panuveitis, sponsored by Lux Biosciences, Inc.. Completed at 41 sites in 7 countries. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2012-10-11.
Sponsored by Lux Biosciences, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Uveitis, Posterior with a site in United States — 1 open to participants now, 3 under way, 1 of them phase 3. Uveitis, Posterior · United States.
Among the 42 studies in Uveitis, Posterior with a site in United States, this one is the 7th largest by enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2007, is one of 15 in phase 3, and was the 4th registered.
61 studies on the registry are indexed under Uveitis, Posterior; 4 are open to participants now.
Browse Uveitis, Posterior studies →1 of the 42 studies in Uveitis, Posterior with a site in United States is open now. Recruiting first, the newest first:
Massachusetts Eye Research and Surgery Institution · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 2 Uveitis, Posterior studies recruiting now, 2 set no upper age limit and none stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 13 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 17 · Phase 4 6
First in 2000; this study’s year is marked. 3 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 218 is above the median of 37 across 45 interventional studies indexed under Uveitis, Posterior.
Median enrollment 33 across the 38 interventional studies, 42 across the 4 observational. Of the 34 that completed or were terminated, 17 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 42 have an industry lead sponsor. The 10 most frequent:
Lux Biosciences, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Lux Biosciences, Inc. has 2 studies filed under Uveitis, Posterior — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 42 studies in Uveitis, Posterior with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Current uveitis therapy must conform to one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Placebo
Drug: LX211
Drug: LX211
Drug: LX211
vitreous haze
Time frame: 16 and 24 weeks
BCVA
Time frame: 24 weeks
The record gives a start of Jan 2007, a primary completion of Nov 2008 and a completion of May 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voclosporin
Lux Biosciences, Inc.